TheEdgeResearch
Home / Stocks / HIND

Vyome Holdings, Inc. (HIND)

NASDAQ Healthcare Biotechnology
$2.26 ▲ +0.44%
Market Cap
$15.9M
Sector
Healthcare
Industry
Biotechnology
Beta
1.49
52-Wk Range
1.75-18.6
CEO
Venkateswarlu Nelabhotla
Country
US
Currency
USD

Vyome Holdings, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Cambridge, MA, US. The stock last traded at $2.26, up 0.44% on the session, giving a market capitalisation of $15.9M. On trailing twelve-month figures it carries a trailing P/E of -0.06, a net margin of -985.5%. Its beta of 1.49 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-0.06
Price / Sales
11.80
Price / Book
1.98
EV / EBITDA
-0.53
Gross margin
48.2%
Operating margin
-401.9%
Net margin
-985.5%
Return on equity
Debt / equity
0.00
Current ratio
4.27
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
18
IPO date
2016-10-06
Headquarters
Cambridge, MA, US
About Vyome Holdings, Inc.

Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.

Comparable companies

Vyome Holdings, Inc. is most often compared with the following Healthcare names:

ARMPCCCCCDXSCGENIMDXIPHANVCTOABISGMOTNXP
More research on HIND
HIND technical analysis HIND TheEdge Score Compare against peers
Open full interactive analysis & DCF →